STOCK TITAN

INTL ISOTOPES INC - $INIS STOCK NEWS

Welcome to our dedicated page for INTL ISOTOPES news (Ticker: $INIS), a resource for investors and traders seeking the latest updates and insights on INTL ISOTOPES stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect INTL ISOTOPES's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of INTL ISOTOPES's position in the market.

Rhea-AI Summary
International Isotopes Inc. (INIS) reports a 10% revenue increase in the twelve months ended December 31, 2023, reaching $12.3 million, the highest in company history. Gross profit rose by 17%, with a $1.1 million increase. Despite a net loss of $869,016 due to a one-time gain in 2022, cash and equivalents improved to $2.7 million. The Theranostics Products segment saw a 13% revenue increase, while Nuclear Medicine Products revenue grew by 10%. Cobalt Products revenue decreased by 10%, and the addition of Medical Devices segment is planned for Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
-
Rhea-AI Summary
International Isotopes Inc. (INIS) has entered into a definitive agreement to sell its depleted uranium deconversion and fluorine processing venture assets to American Fuel Resources, LLC for $12,500,000 cash at closing. The transaction involves a $50,000 prepayment at signing and the remaining $12,450,000 at closing, expected to occur in 12 to 24 months. The deal will allow INIS to focus on the growth of its medical device and theranostics business lines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20%
Tags
none
-
Rhea-AI Summary
International Isotopes Inc. (OTCQB: INIS) reports a 14% increase in revenue for the nine months ended September 30, 2023, reaching $9,120,256, driven by sales of radiochemical and cobalt products. The company also improved its operating loss by 43% and saw a 19% increase in gross profit for the same period. The Radiochemical Products segment experienced significant growth, with a 18% increase in revenue for the three-month period. However, the Nuclear Medicine Segment faced a 1% decrease in revenue during the same period due to global supply constraints of a key isotope raw material. Cobalt product sales decreased by 23% for the three months ended September 30, 2023, but increased by 34% for the nine-month period. President & CEO, Shahe Bagerdjian, expressed satisfaction with the third-quarter results and anticipates continued growth through 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.67%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
INTL ISOTOPES INC

OTC:INIS

INIS Rankings

INIS Stock Data

17.68M
349.48M
72.78%
0%
Instruments and Related Products Manufacturing for Measuring, Displaying, and Controlling Industrial Process Variables
Manufacturing
Link
United States of America
Idaho Falls

About INIS

international isotopes, inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, and radiopharmaceutical and radiochemical contract manufacturing services. the company operates in five segments: nuclear medicine standards, cobalt products, radiochemical products, fluorine products, and radiological services. the nuclear medicine standards segment manufactures sources and standards associated with single photon emission computed tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry. it offers flood sources, dose calibrators, rod sources, flexible and rigid rulers, spot and pen point markers, and various specialty design items. the cobalt products segment produces bulk cobalt; fabricates cobalt capsules for radiation therapy or various industrial applications; and recycles expended cobalt sources. the radiochemical products segment produces and distributes